Ads
related to: diabetes, food and drug administration
Search results
Why This Biotech Stock Crashed 67% To A Two-Year Low
Investor's Business Daily· 19 hours agoThe drug, BMF-291, was in early-stage testing for patients with type 1 and type 2 diabetes. The FDA noted there were possible
Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting — Is It A Buy?
Investor's Business Daily· 15 hours agoShares of companies working on treatments for metabolic dysfunction-associated steatohepatitis, or...
Weight loss medication complete guide: From Wegovy to Mounjaro
The Telegraph via Yahoo News· 3 days agoThe new generation of weight-loss drugs were initially developed to treat diabetes and work by...
Scotiabank cuts Biomea Fusion shares target, notes FDA clinical hold concerns By Investing.com
Investing.com· 21 hours ago(NASDAQ: BMEA) shares, reducing it to $21.00 from the previous $41.00. The adjustment follows the...
Compounded Semaglutide vs. Ozempic: Effectiveness and Safety Review
Healthline· 1 day agoCompounded semaglutide and Ozempic are different products. While both may be used to help manage blood sugar levels in people with type 2 diabetes, Ozempic ...
U.S. FDA places hold on Biomea's diabetes trials
Reuters· 1 day agoBiomea Fusion said on Thursday the U.S. Food and Drug Administration had placed a clinical hold on its ongoing mid ...
Biomea Fusion Down 61% on Clinical Hold for Diabetes Drug
Morningstar· 1 day agoBiomea Fusion shares fell 61% to $4.40 after hours as the company said the Food and Drug Administration placed a full ...
Why Is Biomea Fusion (BMEA) Stock Down 63% Today?
InvestorPlace· 21 hours agoBiomea Fusion (NASDAQ:BMEA) stock is falling hard on Friday after announcing a clinical hold has been put on its Phase I/II clinical trials of BMF-219....
Oral semaglutide could also help treat diabetes, cardiovascular issues
Medical News Today· 3 days agoA new clinical trial in Italy investigates the efficacy of oral semaglutide. Semaglutide and other...
Democrats ramp up patent fight with drug industry in bid to lower prices
Washington Post· 17 hours agoand Rep. Pramila Jayapal (D-Wash.) this week wrote to eight pharmaceutical company CEOs, urging them...